ArticleMedicine2026
Traditional Chinese medicine monotherapy in extensive-stage small cell lung cancer: A Case Report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleSmall cell lung cancer (SCLC) is a highly aggressive malignancy. It typically advances quickly, spreads distantly at an early stage, and carries a dismal prognosis, factors that collectively present formidable obstacles to effective treatment. To date, evidence regarding the effectiveness of traditional Chinese medicine (TCM) used alone in extensive-stage SCLC remains sparse. PATIENT CONCERNS: A 79-year-old man presented with a persistent cough, exertional shortness of breath, hemoptysis with pale-red sticky sputum, and a headache localized to the right forehead, accompanied by difficulty sleeping at night. DIAGNOSES: Imaging and histopathology confirmed extensive-stage SCLC with right frontal lobe metastasis.
interventionsThe patient refused chemotherapy/immunotherapy and received individualized TCM treatment. OUTCOMES: Serial imaging showed a partial response; symptoms markedly resolved; overall survival reached 15.5 months. LESSONS: While findings from a single case must be interpreted cautiously, this experience suggests TCM might contribute to improved outcomes in select patients with extensive-stage SCLC. Further research is needed to clarify its biological mechanisms and define its potential role in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.